Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16984914 | 0.91 | LNPEP (0.46) | CTSLMMEANPEPLNPEPERAP1 | |
| SCHEMBL16984900 | 0.91 | MME (0.42) | CTSLMMEANPEPERAP1ERAP2 | |
| SCHEMBL16984894 | 0.89 | LNPEP (0.44) | CTSLMMEANPEPLNPEPERAP1 | |
| SCHEMBL16925150 | 0.88 | MME (0.50) | CTSLMMEANPEPCTSBACE | |
| SCHEMBL16984903 | 0.88 | CTSL (0.42) | CTSLMMEANPEPERAP1ERAP2 | |
| SCHEMBL16970535 | 0.88 | ACE (0.47) | MMELNPEPERAP1ERAP2CTSC | |
| SCHEMBL16984885 | 0.86 | MME (0.47) | CTSLMMEANPEPLNPEPERAP1 | |
| SCHEMBL16984895 | 0.85 | MME (0.48) | CTSLMMEANPEPCTSBACE | |
| SCHEMBL16984876 | 0.85 | CTSK (0.51) | CTSLERAP1ERAP2CTSB | |
| SCHEMBL16984878 | 0.84 | CTSL (0.51) | CTSLERAP1ERAP2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMA1, PSMB1, PSMB11 | CTSL 1335/4885MME 192/4885ANPEP 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.